Spironolactone in the treatment of chronic central serous chorioretinopathy

Randomized Control Trial of Comparing Spironolactone versus Placebo on Sub Retinal Fluid Thickness and Best Correct visual Acuity of Patients with Chronic Central Serous Chorioretinopathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015092224140N1

Enrollment

Registered

2015-12-20

Start date

2015-10-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Central Serous Chorioretinopathy. Central serous chorioretinopathy Detachment of retinal pigment epithelium

Interventions

Intervention 1: Spironolactone , 25mg, BD, for 3 months. Intervention 2: Placebo, BD, for 3 months.

Treatment - Drugs

Placebo

Spironolactone , 25mg, BD, for 3 months

Placebo, BD, for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. At least 3 months after CSC (according to OCT without SRF decrease of 10% and symptoms for at least 3 months) (chronic changes:pigmentory changes or central macular edema) 2. Do not take any treatment 3. Subfoveal leak and SRF in macula 4. Do not want to do PDT NO pregnancy and breastfeeding 5. NO any ocular pathology other than refractive disorders 6. NO Addison's disease 7. NO hyperkalemia 8. NO oliguria 9. NO acute renal failure 10. Do not take eplerenone 11. Do not take diuretics 12. Do not taking angiotensin-converting enzyme inhibitors 13. Do not take angiotensin receptor blockers 14. Do not take aldosterone inhibitors comets 15. Do not take NSAIDs 16. Do not take heparin or low molecular weight heparin 17. NO high-potassium diet 18. Do not take exogenous potassium 19. Do not take barbiturates 20. Do not have alcohol Consumption 21. Do not use narcotics 22. Do not take lithium 23. Do not use corticosteroid 24. Do not use ACTH 25. Do not take digoxin 26. Do not have Diabetes 27. Do not have eye surgery in three months 28. No Sensitivity to Fluorescein or Indocyanine 29. No hepatic impairment 30. Do not use of contraception methods in women of childbearing age. 31.In cases where the OCT during the first three months of the SRF is less than 10% of patient Exclusion criteria: 1. If patients do not follow according to protocol. 2.If drug complication appear such as : headache or gastrointestinal symptoms.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity. Timepoint: One month and 3 months after treatment. Method of measurement: By snellen chart.;Subretinal fluid thickness. Timepoint: One month and 3 months after treatment. Method of measurement: Optical Coherence Tomography (OCT).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sayyed Amirpooya Alemzadeh

Iran Eye research center

s.amirpooya.alemzadeh@gmail.com+98 21 6655 8811

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026